carbocycl
cytidin
ccyd
broadspectrum
antivir
agent
activ
dna
virus
pox
vaccinia
rna
virus
toga
sindbi
semliki
forest
corona
rna
virus
orthomyxo
influenza
paramyxo
parainfluenza
measl
rhabdo
vesicular
stomat
z
rna
virus
reo
target
enzym
ccyd
suppos
cp
synthetas
convert
utp
ctp
keep
assumpt
observ
ccyd
effect
dosedepend
inhibit
rna
synthesi
virusinfect
uninfect
cell
ii
exogen
addit
either
urd
cr
cyd
revers
antivir
cytocid
activ
ccyd
wherea
addit
dthd
dcyd
fail
select
ccyd
sindbi
vesicular
stomat
reo
viru
markedli
increas
ccyd
combin
cyd
pgml
combin
may
therefor
worth
pursu
chemotherapeut
modal
treatment
viru
infect
carbocycl
nucleosid
analogu
contain
cyclopentyl
pentenyl
ring
instead
usual
ribos
moieti
receiv
consider
attent
potenti
chemotherapeut
ie
antitumor
antivir
agent
carbocycl
analogu
resist
phosphorolysi
nucleosid
phosphorylas
cleav
nglycosid
linkag
regular
nucleosid
therebi
abrog
antivir
antitumor
activ
variou
carbocycl
deriv
pyrimidin
nucleosid
synthes
llo
deriv
antiherp
viru
activ
carbocycl
compound
akin
parent
compound
appear
specif
block
herp
simplex
viru
hsv
replic
carbocycl
analogu
e
bvdu
e
ivdu
shown
react
equal
well
viral
kinas
tk
parent
compound
follow
phosphoryl
virusinfect
cell
triphosph
form
ivdu
carbocycl
counterpart
may
incorpor
dna
cell
cyclopentyl
cyclopentenyl
deriv
cytosin
term
ccyd
cecyd
respect
differ
carbocycl
durd
deriv
activ
tk
hsv
also
herp
virus
varicellazost
vzv
cytomegaloviru
cmv
lo
well
influenza
viru
cecyd
pursu
primarili
antitumor
agent
mode
cytostat
action
attribut
deplet
ctp
pool
result
inhibitori
effect
triphosph
metabolit
cecyd
ctp
synthetas
enzym
convert
utp
ctp
lo
correspond
address
also
ccyd
assum
interact
ctp
synthetas
phosphoryl
intracellularli
ccyd
also
refer
carbodin
prove
activ
variou
influenza
viru
strain
uifro
preliminari
experi
show
efficaci
lethal
influenza
viru
infect
mice
administ
system
intranas
dose
appar
doselimit
toxic
present
studi
undertaken
delin
antivir
activ
spectrum
ccyd
ii
explor
mechan
antivir
action
iii
work
therapeut
modal
increas
antivir
select
compound
ccyd
carbodin
synthes
describ
sheali
odel
l
synthesi
carbocycl
analogu
describ
montgomeri
et
al
ribavirin
virazol
obtain
icn
pharmaceut
costa
mesa
ca
formula
test
compound
present
fig
nucleosid
dthd
uridin
urd
dcyd
cytidin
cyd
obtain
sigma
chemic
co
st
loui
mo
radiolabel
precursor
cell
cell
line
use
antivir
activ
assay
prk
primari
rabbit
kidney
hela
human
epitheli
cell
line
deriv
cervix
carcinoma
vero
simian
fibroblast
cell
line
deriv
african
green
monkey
kidney
human
embryon
lung
diploid
fibroblast
atcc
ehsm
human
embryon
skinmuscl
fibroblast
hk
human
kidney
fibroblast
cell
line
human
epitheli
cell
line
deriv
larynx
carcinoma
rabbit
kidney
cell
line
simian
epitheli
cell
line
deriv
african
green
monkey
kidney
simian
fibroblast
cell
line
deriv
african
green
monkey
kidney
babi
hamster
kidney
fibroblast
cell
line
murin
fibroblast
deriv
balbc
mous
embryo
cell
grown
eagl
minimum
essenti
medium
supplement
fetal
calf
serum
antivir
activ
inhibit
virusinduc
cytopathogen
measur
follow
wellestablish
procedur
viral
cytopathogenec
assay
viru
inoculum
ccid
per
microtit
well
correspond
viru
stock
dilut
prove
infect
cell
cultur
inhibit
viru
multipl
measur
hela
cell
infect
vesicular
stomat
viru
follow
wellestablish
procedur
particular
assay
viru
inoculum
pfu
plaqu
form
unit
per
petri
dish
antimetabol
activ
inhibit
host
cell
macromolecul
dna
rna
protein
synthesi
monitor
incorpor
dthd
urd
leu
respect
incub
period
hr
exponenti
grow
cell
presenc
test
compound
cytocid
activ
inhibit
vero
hela
cell
prolifer
assess
exponenti
growth
phase
monitor
count
number
viabl
cell
follow
stain
trypan
blue
procedur
similar
describ
previous
murin
leukemia
cell
ccvd
wasevalu
comparison
two
broadspectrum
antivir
agent
cc
ado
ribavirin
wide
varieti
rna
dna
virus
tabl
ccyd
show
mark
activ
follow
virus
vaccinia
vesicular
stomat
reo
parainfluenza
sindbi
semliki
forest
measl
corona
tkherp
simplex
influenza
sspe
virtual
inact
tk
herp
simplex
polio
coxsacki
rhino
respiratori
syncyti
viru
tabl
compar
ccyd
activ
vaccinia
vesicular
stomat
prk
parainfluenza
less
activ
virus
ribavirin
less
activ
ccyd
virus
test
except
polio
coxsacki
respiratori
syncyti
viru
influenza
ribavirin
prove
equal
effect
ccyd
tabl
neither
ccyd
ribavirin
activ
human
immunodefici
viru
type
concentr
concentr
requir
inhibit
growth
host
lymphocyt
cell
respect
data
shown
antivir
potenc
antivir
agent
gener
antiherp
drug
particular
may
differ
consider
depend
choic
cell
ccyd
evalu
activ
vesicular
stomat
viru
wide
varieti
cell
line
tabl
wherea
ccyd
inhibit
virusinduc
cytopathogenec
prk
hela
ehsm
vero
balb
fail
cell
line
ie
bscia
antivir
activ
ribavirin
also
vari
consider
one
cell
line
anoth
moreov
celldepend
pattern
antivir
effect
ccyd
ribavirin
also
differ
one
anoth
tabl
ie
activ
vesicular
stomat
viru
cell
ccyd
show
much
activ
wherea
inact
cell
ccyd
prove
effect
ribavirin
inact
vesicular
stomat
viru
prk
cell
ccyd
show
activ
wherea
ribavirin
quit
activ
hk
cell
ccyd
fail
show
activ
inhibitori
effect
ccyd
virusinduc
cytopathogen
tabl
reflect
inhibit
viru
multipl
ascertain
follow
viru
yield
hela
cell
infect
vesicular
stomat
viru
treat
vari
concentr
lo
pgml
ccyd
compound
effect
dosedepend
reduct
viru
yield
whether
viru
content
determin
hr
infect
fig
maximum
reduct
viru
yield
log
achiev
concentr
loopgml
hr
post
infect
shown
varieti
cell
tabl
ccyd
prove
inhibitori
host
cell
dna
rna
synthesi
monitor
incorpor
dthd
urd
respect
within
rang
concentr
pgml
exhibit
antivir
activ
tabl
inhibitori
dna
rna
synthesi
ccyd
affect
protein
synthesi
examin
cell
line
tabl
doserespons
curv
inhibitori
effect
ccyd
host
cell
rna
synthesi
vero
cell
present
fig
establish
whether
ccyd
effect
compar
inhibit
viral
rna
synthesi
vero
cell
infect
either
sindbi
viru
reoviru
treat
actinomycin
pgml
complet
block
host
cell
dnadirect
rna
synthesi
remain
viral
rnadirect
rna
synthesi
inhibit
ccyd
concentr
slightli
lofold
higher
requir
inhibit
host
cell
rna
synthesi
uninfect
cell
treat
actinomycin
fig
obtain
insight
mechan
concentr
requir
reduc
incorpor
radiolabel
precursor
data
repres
averag
valu
three
separ
experi
action
ccyd
attempt
undertaken
revers
antivir
activ
exogen
addit
nucleosid
deoxynucleosid
dthd
dcyd
counteract
antivir
activ
ccyd
vero
hela
cell
infect
either
sindbi
reo
vesicular
stomat
viru
tabl
howev
ribonucleosid
urd
cyd
complet
abrog
antivir
effect
ccyd
ad
concentr
loopgml
evid
rais
virusinhibitori
concentr
ccyd
follow
addit
urd
cyd
loopgml
tabl
ad
lopgml
urd
brought
sofold
cyd
lofold
rais
virusinhibitori
concentr
ccyd
urd
cyd
revers
antivir
action
ccyd
also
abrog
cytocid
effect
tabl
respect
cyd
effici
urd
concentr
pgml
cyd
reduc
cytocid
action
ccyd
wherea
similar
effect
accomplish
urd
concentr
pgml
neither
dthd
dcyd
counteract
cytocid
effect
ccyd
hela
vero
cell
even
ad
concentr
pgml
tabl
antivir
activ
spectrum
ccyd
clearli
differ
ribavirin
activ
picornavirus
polio
coxsacki
wherea
ccyd
tabl
convers
ccyd
quit
activ
variou
virus
ie
sindbi
reo
corona
measl
tkherp
simplex
sensit
slightli
sensit
ribavirin
ribavirin
assum
intereact
number
target
protein
ie
imp
dehydrogenas
mrna
enzym
viral
mrna
polymeras
complex
protein
antivir
activ
spectrum
ccyd
also
differ
ccado
latter
much
less
activ
inact
sindbi
corona
influenza
tkherp
simplex
tabl
also
ccyd
ccado
show
mark
differ
activ
vesicular
stomat
viru
depend
natur
cell
line
use
tabl
cc
ado
assum
interact
sadenosylhomocystein
hydrolas
key
enzym
transmethyl
reaction
seri
acycl
carbocycl
adenosin
analogu
includ
cc
ado
close
correl
found
betweeen
inhibitori
effect
sadenosylhomocystein
hydrolas
activ
vaccinia
vesicular
stomat
viru
inspect
activ
spectrum
ccyd
rel
spectra
ribavirin
tabl
infer
ccyd
must
achiev
antivir
activ
mechan
differ
mode
action
either
ribavirin
shannon
et
al
demonstr
ccyd
phosphoryl
intracellularli
cctp
caus
specif
decreas
ctp
pool
point
inhibitori
effect
nucleosid
ad
cctp
ctp
synthetas
level
last
step
de
nouo
biosynthesi
ctp
start
aspart
carbamoyl
phosphat
fig
ccyd
convert
exert
inhibitori
effect
ci
p
synthetas
subject
prematur
degrad
pyrimidin
nucleosid
phosphorylas
unpublish
data
c
desgrang
e
de
clercq
indic
ccyd
substrat
either
urd
phosphorylas
dthd
phosphorylas
remain
establish
effici
enzym
ccyd
convert
inhibitori
effect
ccyd
cellular
viral
rna
synthesi
fig
agreement
postul
inhibit
ctp
synthetas
cctp
also
consist
inhibit
ctp
synthesi
inhibitori
effect
ccyd
dna
synthesi
tabl
inhibit
ctp
synthesi
also
lead
reduct
suppli
pyrimidin
deoxynucleosid
dctp
dttp
outlin
fig
fig
also
clear
mode
action
ccyd
base
upon
inhibit
utp
ctp
step
addit
suppli
utp
ctp
urd
cyd
salvag
pathway
may
expect
overcom
inhibitori
effect
ccyd
premis
born
antivir
activ
tabl
cytocid
activ
select
antivir
agent
howev
antivir
select
ccyd
markedli
increas
combin
cyd
addit
cyd
pgml
revers
cytocid
activ
ccyd
significantli
greater
extent
tabl
antivir
activ
tabl
thu
result
mark
increas
antivir
select
index
ccyd
tabl
mark
increas
select
observ
vero
hela
cell
infect
either
rna
viru
sindbi
rna
viru
reo
rna
viru
vesicular
stomat
combin
ccyd
cyd
ugml
repres
new
therapeut
modal
deserv
explor
treatment
variou
rna
viru
infect
acknowledgementsw
thank
anita
van
lierd
frieda
de
meyer
ria
van
berwaer
excel
technic
help
christian
callebaut
dedic
editori
assist
revers
exogen
addit
urd
cyd
dthd
dcyd
thu
ctp
synthetas
consid
import
target
design
broadspectrum
antivir
compound
ctp
synthetas
also
need
host
cell
rna
dna
synthesi
may
also
serv
target
enzym
antitumor
agent
fact
cecyd
assum
exert
antitumor
ie
cytocid
properti
inhibit
ctp
synthetas
deplet
intracellular
ctp
pool
ctp
synthetas
act
target
enzym
antivir
cytocid
activ
ccyd
could
ccyd
envisag
exert
select
antivir
action
ratio
inhibitori
concentr
cell
growth
exponenti
grow
cell
inhibitori
concentr
viral
cytopathogen
stationari
celi
tabl
ccyd
appear
particularli
